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Twenty-six patients with severe COPD or asthma completed standard questionnaires before, and 2 months after, 
starting home nebulized bronchodilator therapy. Patients’ perceived illness severity and their expectations of 
treatment with regard to symptoms were examined in the first questionnaire, and outcome was assessed in the 
second. Before treatment started patients expected a definite improvement in all symptoms studied. After treatment 
the group showed only a marginal subjective improvement in all symptoms. The improvement attained with regard 
to breathlessness, ability to get out and about, and general quality of life was significantly lower than had been 
expected. While home nebulized bronchodilator therapy is well tolerated and confers some subjective benefit in 
selected individuals, patients appear to have unrealistically high expectations of treatment. 
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Introduction 
The recent proliferation in availability of inhaled drug 
delivery systems has been paralleled by increasing debate 
over the most appropriate mode of delivery to prescribe for 
individual patients with chronic airflow limitation (1,2). 
Domiciliary nebulizers are often prescribed for patients 
with chronic asthma and chronic obstructive pulmonary 
disease (COPD) who have considerable practical difficulty 
with other forms of bronchodilator delivery, or who derive 
little clinical benefit from them. While evidence on the 
effectiveness of home nebulized bronchodilator therapy has 
been conflicting (335), in recent years evidence has begun to 
emerge pointing to the relative long-term safety and accept- 
ability of home nebulized therapy in carefully selected 
groups of patients (6,7). 
Most studies examining the effects of home nebulizer 
therapy have concentrated on analysing symptoms or 
objective measurements of lung function, and few have 
considered the expectations of patients about to start 
treatment with a home nebulizer. We aimed to study the 
expectations of such patients, particularly with regard to 
the nebulizer’s effect on symptoms. 
Patients and Methods 
The study was based on two standard questionnaires 
completed by patients before, and 2 months after starting 
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domiciliary nebulized bronchodilator therapy. The ques- 
tionnaires were designed in keeping with the guidelines 
described by Stone (8). 
Thirty-nine consecutive patients referred by local 
consultants for home nebulized treatment were asked to 
complete the questionnaires. Six patients declined to 
participate, and seven failed to return the second question- 
naire, leaving 26 responses for analysis. Fifteen of the 
respondents were female. The primary diagnosis was 
COPD in 18 cases and asthma in six. One patient had 
pulmonary fibrosis in addition to ‘reversible airflow 
obstruction’ and one patient had ‘chronic airflow limita- 
tion’. Thirteen of 18 patients had a documented response to 
bronchodilators above that expected by normal variability 
(9). Eight patients had no documented test with broncho- 
dilators in the laboratory (of whom four had a diagnosis of 
asthma). The mean FEV, was 0.89 1 (SD 0.53) and the mean 
vital capacity 1.94 1 (SD 0.68). Twenty-two patients had 
received treatment via a nebulizer in the acute setting at 
least once before (18 in hospital, four prescribed by 
the general practitioner) and one had used a nebulizer 
previously in an elective setting. 
At the time of receiving the home nebulizer, 23 patients 
were being treated with inhaled &agonists and 21 with 
inhaled anticholinergics. Sixteen were on treatment with 
an inhaled glucocorticoid and two were taking oral 
prednisolone. Six were being treated with an inhaled long- 
acting &agonist and four were taking an oral theophylline. 
The first questionnaire was designed to assess the 
patients’ treatment, their perceived severity of illness, and 
their expectation of how the nebulizer would affect 
symptoms. Patients were asked to indicate whether they 
expected certain symptom complexes (breathlessness, 
ability to get out and about, cough, perceived ‘number of 
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TABLE 1. Patients’ descriptions of symptoms before home nebulized bronchodilator therapy 
None Mild Severe Very severe No response 
Breathlessness at rest 2 10 10 4 
Breathlessness on exertion 0 1 10 15 
Cough 4 15 4 2 1 
Nocturnal symptoms 0 10 8 8 
Difficulty getting out and about 1 3 13 9 
TABLE 2. Expected and actual symptom scores. Patients ranked whether they expected each symptom 
to become much better, better, unchanged or worse (before starting home nebulizers) and used the 
same ranking to describe the actual change in each symptom 2 months after starting home 
nebulizers. ‘Much better’ received a score of 2, ‘better’ 1, ‘unchanged’ 0, ‘worse’ - 1. Results 
expressed as mean (SD). Patients answering ‘don’t know’ in first questionnaire excluded 
n Expected score Actual score 
Breathlessness 
Ability to get 
out and about 
Cough 
Number of 
chest infections 
Quality of sleep 
Quality of life 
26 
21 
19 
17 
22 
22 
1.35 (0.48) 0.69 (0.84) P<O.O05 
1.10 (0.54) 0.24 (0.77) P<O.O05 
0.68 (0.75) 0.74 (0.73) n.s. 
0.65 (0.61) 0.29 (0.69) n.s. 
0.73 (0.63) 0.41 (0.67) ns. 
1.04 (0.58) 0.46 (0.67) P<O.O05 
n.s.: not significant 
chest infections’, quality of sleep, and general quality of life) 
to get worse, stay unchanged, get better, or get much better 
(‘don’t know’ was also an available option). The response 
for each symptom was graded from - 1 (worse) to 2 (much 
better). The use of the nebulizer was demonstrated to all 
patients, clear instructions were given regarding the pre- 
scribed frequency of use, and an instruction leaflet was 
issued. 
Two months after starting treatment the second 
questionnaire was sent by post. This assessed the perceived 
effect of the nebulizer on the same symptom complexes 
addressed in the first questionnaire, using the same avail- 
able responses, and in addition enquired about changes in 
treatment, frequency of nebulizer use, and side-effects. 
Intra-patient comparisons of symptom scores were car- 
ried out using Wilcoxon’s signed rank test, with significance 
taken as PcO.05. 
Results 
Before home nebulizers were instituted breathlessness on 
exertion and difficulty getting out and about were the most 
troublesome symptoms, being described as severe or very 
severe by 25 and 22 patients respectively (Table 1). 
The daily frequency of nebulizer use matched that pre- 
scribed in all cases. After 2 months of home nebulized 
bronchodilators two patients with COPD had stopped 
using metered dose inhalers. Three patients reported side- 
effects of nebulized bronchodilator therapy (nausea and 
vomiting; sore eyes and a facial rash; and dry throat). 
Discussion 
The average expectation was for an improvement in all Recent evidence from a prospective study has suggested 
symptom complexes studied (Table 2). The greatest benefit that the long-term use of home nebulized bronchodilators is 
was expected for breathlessness, general quality of life, and 
ability to get out and about. 
After home nebulized bronchodilators were started there 
was a small mean subjective improvement in all symptom 
complexes (Table 2). For the symptom complexes in which 
expectation of improvement had been highest (breathless- 
ness, ability to get out and about, and general quality of 
life), the actual perceived changes after treatment were, 
statistically, significantly lower than had been expected 
(Table 2). In contrast, where expectation for improvement 
in a given symptom was low before treatment started, no 
statistically significant difference emerged when comparing 
expected and actual outcomes. No differences in the degree 
of symptomatic improvement were found when comparing 
patients with and without documented bronchodilator 
reversibility (data not shown). 
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safe when compared to long-term metered dose inhaler use, 
and confers continued spirometric advantage for at least 
3 years (7). We have studied the views of a small group of 
patients with severe chronic airflow obstruction starting 
home nebulized bronchodilators for the first time. Using 
a simple scoring system we found that, in the shortterm, 
introduction of the nebulizer resulted in average subjective 
benefit in all symptoms studied. These findings are generally 
in keeping with findings elsewhere (4,6). However, the 
subjective improvements in symptoms were generally small, 
the greatest benefits being observed in perceived breathless- 
ness and cough. The observed improvement in symptoms 
might indeed be slightly over-estimated, if one were to 
assume that seven of 33 patients failing to return the 
second questionnaire were non-compliant on the grounds 
of minimal benefit. 
The patients studied generally tolerated the introduction 
of nebulized bronchodilator therapy well with only three 
out of 26 patients reporting side-effects, which is lower than 
rates described elsewhere (4,6). 
In general patients’ expectations of symptomatic 
improvement far exceeded the subjective improvement 
derived in the shortterm from nebulized therapy. This trend 
was most pronounced when the initial expectation of 
improvement was highest. This implies that most patients 
have unrealistically high expectations of symptomatic 
improvement. By identifying those symptom complexes for 
which expectation out-weighs perceived benefit most strik- 
ingly (e.g. breathlessness and ability to get out and about), 
it should be possible to give patients advice relating to 
degrees of improvement that might realistically be expected. 
Such advice could be incorporated into the education given 
to patients before starting treatment, a process known to 
improve successful implementation of therapy in children 
(10). 
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